Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 208

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 208
---
20.4 million shares of Aptorum’s common stock with an estimated fair value of $18.7 million (based on the closing price of Aptorum’s Class A Ordinary Shares on July 11, 2025, of $0.94 per share). Following the Merger, Aptorum’s existing shareholders will own 8,536,034shares of the Combined Company’s common stock and Aptorum’s place of incorporation will be moved from the Cayman Islands to Delaware and it will have one class of common stock. The preferred stock to be issued in exchange for Aptorum’s Class B Ordinary shares will be non -votingand non -convertiblebut will entitle the holders to 70% of the net proceeds, if any, realized by the Combined Company following any sale of Alzheon common stock currently held by the Company. The Company’s board of directors believed that, as a result of arm’s length negotiations with DiamiR, the Company and its management team negotiated the most favorable implied value and equity split for its stockholders that DiamiR was willing to agree to, and that the terms of the Merger Agreement include the most favorable terms to the Company in the aggregate to which DiamiR was willing to agree. Immediately prior to signing the Merger Agreement, the Company’s stock price was $0.94 per share, as quoted on Nasdaq on July 11, 2025. Aptorum and DiamiR agreed that at the time of closing of the Merger the relative valuation would be subject to adjustment to reflect the agreed upon 70/30 allocation. The Company’s board of directors also believed, after a thorough review of strategic alternatives and discussions with the Company’s senior management and legal counsel, that the proposed Merger is more favorable to its stockholders than the potential value that might have resulted from other strategic options available to Company. After considering these and other factors, the Company’s board of directors approved the Merger, which the Company board of directors believes better positions Company for long -termsuccess. Aptorum, in connection with the proposed merger with DiamiR, may raise additional capital through private or public offerings, which proceeds are intended for working capital, to support DiamiR’s biopharma services franchise, increase lab throughput, advance pipeline products, including CogniMIR ®, test for glioblastoma and other LDTs under CLIA guidelines, and other general corporate purposes. Although no financing is required to close the Merger the parties are contemplating to